Andreas Rummelt
Directeur/Membre du Conseil chez ASTRAZENECA PLC
Fortune : 4 M $ au 31/05/2024
Profil
Dr. Andreas Rummelt is a Chief Executive Officer & Partner at Interpharmalink and an Independent Director at Alvogen Emerging Markets Holdings Ltd.
He is on the Board of Directors at AstraZeneca PLC, LEUKOCARE AG, Selica Ltd., Alvogen Emerging Markets Holdings Ltd.
and Cypralis Ltd.
Dr. Rummelt was previously employed as a Vice Chairman by Acino Holding AG, an Independent Director by Alexion Pharmaceuticals, Inc., a Group Head-Quality Assurance by Novartis International AG, a Head-Quality Assurance & Technical Operations by Novartis AG, a Chief Executive Officer by Sandoz Pharmaceuticals AG, and a CEO & Head-Technical Operations by Novartis Pharmaceuticals UK Ltd.
He also served on the board at Eon Labs, Inc., Famar SA, Habasit AG, Mipharm SpA and Xellia Pharmaceuticals ApS.
He received his doctorate degree from Friedrich-Alexander University of Erlangen-Nuremberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASTRAZENECA PLC
0,00% | 31/12/2023 | 27 205 ( 0,00% ) | 4 M $ | 31/05/2024 |
Postes actifs de Andreas Rummelt
| Sociétés | Poste | Début |
|---|---|---|
| ASTRAZENECA PLC | Directeur/Membre du Conseil | 01/08/2021 |
LEUKOCARE AG
 LEUKOCARE AG Medical/Nursing ServicesHealth Services LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany. | Directeur/Membre du Conseil | 15/07/2016 |
Cypralis Ltd.
 Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Directeur/Membre du Conseil | - |
| Interpharmalink | Directeur Général | 01/01/2011 |
| Selica Ltd. | Directeur/Membre du Conseil | - |
Alvogen Emerging Markets Holdings Ltd.
 Alvogen Emerging Markets Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009. | Directeur/Membre du Conseil | - |
Anciens postes connus de Andreas Rummelt
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 14/07/2021 |
| ACINO HOLDING AG | Directeur/Membre du Conseil | 17/12/2013 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2010 |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Andreas Rummelt
| Friedrich-Alexander University of Erlangen-Nuremberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 15 |
|---|---|
Eon Labs, Inc.
 Eon Labs, Inc. Pharmaceuticals: MajorHealth Technology Eon Labs, Inc. manufactures pharmaceuticals and generic drugs. They produce drugs in oral dosage variety and in both immediate and extended release delivery systems. Their products are used in treating arthritis, ulcers, epilepsy, infections and obsessive-compulsive disorder. The company was founded in 1992 and is headquartered in Lake Success, NY. | Health Technology |
Novartis Pharmaceuticals UK Ltd.
 Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Acino International AG
 Acino International AG Pharmaceuticals: MajorHealth Technology Acino International AG develops and manufactures pharmaceuticals in novel drug delivery form. The firm provides drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. It offers abelcet, bactiflox, clopacin, dolonica, hydronica, neurorubine, olfen and spasfon. The company was founded in 1836 and is headquartered in Zurich, Switzerland. | Health Technology |
Famar SA
 Famar SA Pharmaceuticals: MajorHealth Technology Famar SA provides contract manufacturing and development services to the pharmaceutical, health, and beauty industries. It offers product transfers and industrialization, technical research and development, packaging, and logistics services. The company was founded in 1949 and is headquartered in Athens, Greece. | Health Technology |
| Selica Ltd. | |
| Interpharmalink | |
Sandoz Pharmaceuticals AG
 Sandoz Pharmaceuticals AG BiotechnologyHealth Technology Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland. | Health Technology |
Xellia Pharmaceuticals ApS
 Xellia Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals ApS manufactures pharmaceutical products. Its products include pharmaceutical ingredients, finished dosage forms and novel anti infective pipeline. The company was founded in 1959 and is headquartered in Copenhagen, Denmark. | Health Technology |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Habasit AG
 Habasit AG Industrial MachineryProducer Manufacturing Habasit AG manufactures conveyor belts. The firm provides inventory, fabrication, assembly and service facilities. The firm's products include processing belts, installation support and after sales service as well as power transmission. The company was founded in 1946 and is headquartered in Reinach, Switzerland. | Producer Manufacturing |
Mipharm SpA
 Mipharm SpA Pharmaceuticals: MajorHealth Technology Mipharm SpA manufactures specialty pharmaceuticals and generic drugs. It operates as a third party manufacturing site for various pharmaceutical brands as well as offers integrated services such as packagaing, research, and development. The company was founded by Giuseppe G. Miglio in January 1998 and is headquartered in Milan, Italy. | Health Technology |
Cypralis Ltd.
Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Health Technology |
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany. | Health Services |
Alvogen Emerging Markets Holdings Ltd.
Alvogen Emerging Markets Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of Celtic Holdings SCA, Alvogen Emerging Markets Holdings Ltd. is a Chinese pharmaceutical company that offers high-quality, affordable generic medications to reduce healthcare costs globally. The company is based in Wanchai, Hong Kong. The company's growth strategy is fueled by a unique portfolio of high-quality and difficult-to-make pharmaceutical products. Alvogen's sister company, Alvotech, specializes in the development and manufacturing of high-quality biosimilar medicines. The company was founded in 2009 by Vilhelm Róbert Wessman, who has been the CEO since 2009. | Health Technology |
